Citation Information :
Patil SM, Bankar MP. Study of Correlation between the Paraoxonase 1 (PON1) Activity and Lipid Profile in Various Types of Coronary Heart Disease. Indian J Med Biochem 2021; 25 (2):65-70.
Aim and background: Coronary heart disease (CHD) is the major cause of mortality and morbidity worldwide. Human serum paraoxonase-1 is a high-density lipoprotein (HDL)-bound enzyme exhibiting anti-atherogenic properties.
Objective: The current study aimed to determine the serum paraoxonase-1 activity and lipid profile with CHD in addition to correlate the relationship between serum high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL) cholesterol, and paraoxonase-1 level in patients with CHD.
Materials and methods: In the present case-control study, 265 with coronary artery disease (age range 26–75) and 120 age- and sex-matched healthy controls were recruited. Serum paraoxonase activity was measured spectrophotometrically by using phenylacetate as substrate by kinetic assay while lipid profile was analyzed by an enzymatic method by cholesterol oxidase peroxidase (CHOD-PAP) method of total cholesterol and HDL-C and glycerol 3-phosphate oxidase (GPO-PAP) method of triglyceride. Values were expressed as mean ± standard deviation and data from patients and controls were compared by using the Student\'s “t” test.
Results: Serum paraoxonase-1 activity was significantly (p < 0.01) decreased in CHD when compared with healthy controls. Similarly, there was a significant difference between mean values of paraoxonase-1 when all CHD groups compared with each other (p < 0.01). Correlation between paraoxonase-1 vs HDL-C was positive in stable angina (Karl Pearson\'s correlation coefficient r = 0.04671), myocardial infarction (MI) (r = 0.2643), and controls (r = 0.06384) and it was negative in unstable angina (UA) (r = −0.098). There was negative correlation between paraoxonase-1 vs low-density lipoprotein (LDL)-cholesterol in stable angina (r = −0.0291), MI (r = −0.2265), and control group (r = −0.1767), and was positive in UA (r = 6185).
Conclusion: Low paraoxonase-1 may be reducing the capacity of HDL to prevent the oxidation of LDL cholesterol, therefore, lead to CHD. So interventional means of dietary antioxidants to conserve or even to raise paraoxonase-1 activity may contribute to attenuation of atherogenesis.
Mohan H. Human serum paraoxonase 1 (PON1) is an HDL-C-bound enzyme considered to be the major risk. Textbook of pathology forward ivan danjanov. 5th ed., Anshan Publishers; 2005. pp. 305–326.
Gupta N, Gill KD, Singh S, Paraoxonase 1 (PON1) activity, polymorphisms and coronary artery disease. Coronary Artery-New Insights and Novel Approaches. Available from:http://www.intechopen.com/books/coronary-artery-disease-new-sights-and-novel-approaches/paraoxonase-1-pon1-activity-polymorphisms and-coronary-artery-disease, pp. 115-133.
World Health Organization. Disease and injury, regional estimates, cause specific estimates for 2008. World Health Organization, 2011.
Rad EM, Assadi F. Management of hypertension in children with cardiovascular disease and heart failure. Int J Prev Med 2014;5(Suppl 1):S10–S16.
Agouridis AP, Rizos CV, Elisaf MS, et al. Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? Rev Diabet Stud 2013;10(2-3):171–190. DOI: 10.1900/RDS.2013.10.171.
Ferrières J, Amber V, Crisan O, et al. Total lipid management and cardiovascular disease in the dyslipidemia international study. Cardiology 2013;125(3):154–163. DOI: 10.1159/000348859.
Sexena T, Agarwal BK, Kare P. Serum paraoxonase activity and oxidative stress in acute myocardial infarction patients. Biomed Res 2011;22(2):215–219.
Jayakumar N, Thejaseebai. G. High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease. J Clin Biochem Nutr 2009;45(3):278–284. DOI: 10.3164/jcbn.08-255.
Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21(9):1451–1457. DOI: 10.1161/hq0901.094247.
Herbert K. Lipids in clinical chemistry, theory analysis and co-relation Kaplan LA, Pesce AJ, ed., Toronto: C.V. Mosby; 1984. pp. 1182–1230.
Kaplan A, Lavernel LS. Lipid metabolism, in clinical chemistry: interpretation and techniques. 2nd ed., Philadelphia: Lea and Febiger; 1983. pp. 333–336.
McGowan MW, Artiss JD, Strandbergh DR, et al. A peroxidase coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983;29(3):538–542. DOI: 10.1093/clinchem/29.3.538.
Young DS. Effects of drugs on clinical laboratory tests. 4th ed., Washington DC: ACCC Press; 1995.
Klaus L, Flatter B, Augustin E. Arylesterase in serum elaboration and clinical application of a fixed incubation method. Clin Chem 1979;25(10):1714–1720. DOI: 10.1093/clinchem/25.10.1714.
Akcay AB, Camseri A, Ozcan T, et al. The relationship between paraoxonase_1 activity and coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dem Ars-Arch Turk Soc Cardiol 2011;39(5):371–377. DOI: 10.5543/tkda.2011.01382.
Camps J, Marsillach J, Joven J. Measurement of serum paraoxonase – 1 activity in the evaluation of liver function. World J Gastroenterol 2009;15(16):1929–1933. DOI: 10.3748/wjg.15.1929.
Feingold KR, Memon RA, MoserAH, et al. Paraoxonase activity in serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998;139(2):307–315. DOI: 10.1016/s0021-9150(98)00084-7.
Kabaroglu C, Mutaf I, Boydak B, et al. Association between serum paraoxonase activity and oxidase stress in acute coronary syndromes. Acta Cardial 2004;59(6):606–611. DOI: 10.2143/AC.59.6.2005242.
Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999;26(7-8):892–904. DOI: 10.1016/s0891-5849(98)00272-x.
Juretic D, Motejlkova A, Kunovic B, et al. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus. Acta Pharm 2006;56(1):59–68.
Mackness B, Mackness MI, Durrington PN, et al. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest 2000;1(1):4–10. DOI: 10.1046/j.1365-2362.2000.00580.x.
Ayub A, Mackness M, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19(2):330–335. DOI: 10.1161/01.atv.19.2.330.
Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299(11):1265–1276. DOI: 10.1001/jama.299.11.1265.
Suvarna R, Rao SS, Joshi C, et al. Paraoxonase activity in activity in type 2 diabetes mellitus patients with and without complication. J Clin Diagnos Res 2011;5(1):63–65.
Chavan V, Patil N, Karnik ND. Study of leukocytic hydrolytic enzymes in patients with acute stage of coronary heart disease. Indian J Med Sci 2007;61(2):73–82. DOI: 10.4103/0019-5359.30347.
Saha N, Roy AC, Teo SH, et al. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991;40(4):277–282. DOI: 10.1111/j.1399-0004.1991.tb03096.x.
Sorenson RC, Bisgair CL, Viram MA, et al. Human serum paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDL by binding phospholipids: apolipoprotein A-I stabilies activity. Arterioscler Thromb Vasc Biol 1999;19(9):2214–2225. DOI: 10.1161/01.atv.19.9.2214.
Gupta N, Singh S, Matura N, et al. Paraoxonase 1 plolymorphisms, haplotypes and activity in predicting CAD risk in North-west Indian Punjabis. PLoS One 2011;6(5):e17805. DOI: 10.1371/journal.pone.0017805.
Kumar A, Sivakanesan R, Nagtilak S. Serum paraoxonase activity in normolipidaemic patients with acute myocardial infarction. J Clin Diagnos Res 2008(2):1052–1056.